Monkeypox cases are dropping. But the Administration keeps expanding the targeted population for the vaccines and trying every which way to jab us

https://merylnass.substack.com/p/monkeypox-cases-are-dropping

Meryl Nass

3 hr ago

There have been 2 deaths in Americans who had monkeypox. Both were said to be severely immunocompromised.

Sept. 12, 2022, 12:33 AM EDT / Updated Sept. 13, 2022, 12:20 PM EDT

The Los Angeles County health department on Monday confirmed the first death from monkeypox in the U.S.

In
a statement, the department said the patient was severely
immunocompromised and had been hospitalized, but did not provide further
details.

The Centers for Disease Control and Prevention has confirmed the death as well, the department said.

In
Texas, health officials are still investigating the death of a person
with monkeypox. When the death was reported on August 29, the Texas
Department of State Health Services said the patient was diagnosed with
monkeypox in the Houston area and was “severely immunocompromised.” But
it’s not yet known whether monkeypox was the cause of death.

There was also one reported death in a Hollywood makeup artist 9 days after receiving a monkeypox vaccine injection. 

Fortunately, monkeypox cases have been steadily dropping over the past 3 weeks.

As Demand for the Monkeypox Vaccine Stalls, Outreach Goes Hyperlocal

Politico reported:

Federal health officials working to stem the monkeypox
outbreak are shifting tactics in their immunization campaign as
interest in the vaccine wanes and gaps in getting the shot to
communities of color persist.

Earlier this summer,
eager people snapped up vaccination appointments in cities from New York
to Los Angeles. But a POLITICO review of a Biden
administration pilot program that began last month to offer shots at
large events found that supply outpaced demand, a trend mirrored
nationwide as vaccine uptake has slowed.

Now the administration says it’s widening the net, creating another pilot to send vaccines to smaller venues and clinics.

I
have pointed out that vaccine did not prevent monkeypox in monkeys. It
did generate antibody levels…but without a correlate of protection
antibody levels don’t mean much. All vaccine candidates generate
antibodies of some kind. In an apparent attempt to show the vaccine
“works”, the manufacturer has released some unpublished data, according
to CIDRAP at the University of Minnesota:

In contrast to a recent Dutch preprint that cast doubt on
the efficacy of Bavarian Nordic’s Jynneos (modified vaccinia Ankara
[MVA]) vaccine to produce significant neutralizing antibodies to
monkeypox, the company has released its own preprint study showing
that single and two-dose Jynneos vaccinations administered
subcutaneously induced durable neutralizing antibody responses in
healthy volunteers.

Results were comparable to older-generation replicating smallpox vaccines.

But
here’s the thing: The CDC gave the vaccine to 1000-1600 healthcare
workers in an area of the Congo where many were expected to be exposed.
Vaccinations began in 2017 and were completed by 2020 or earlier. 

The 2017 clinicaltrials.gov report of this trial says it will enroll 1600 healthcare workers. The 2018 publication
describing the logistics of the trial says the target enrollment was
1000. This publication also states that “16 weeks were required for
initial enrollment of participants.”  It further describes its
methodology:

Serologic monitoring of study
participants will continue at roughly 6-month intervals until the
two-year timepoint is reached. Until that time, the study team will
continue to collect information pertaining to participants’ occupational
exposures to MPX cases—presumptive and confirmed—, MPX infection
status, and possible vaccine adverse events. Finally, as a surrogate
measure for immunization efficacy, we will measure participants’ serum
orthopoxvirus antibody titers and will assess whether specific
participant characteristics (e.g., age, sex, prior smallpox
immunization) are associated with more enduring antibody levels…

Understanding
the performance parameters of IMVAMUNE [one of the many earlier names
of Jynneos—Nass] under conditions of natural orthopoxvirus transmission will build confidence
in its use as a preventive measure for many populations potentially at
risk, including HCWs, and, in the future, perhaps hunters or other
groups with elevated risk.

Yet
CDC has breathed not a word of the results of this extensive field
trial, the only trial of efficacy—ever—for this vaccine.

If the
results were positive, don’t you think CDC would be shouting them from
the rooftops as it seeks more and more recipients for its monkey
business vaccine?

And now they want our children to join the experiment. Or maybe it is not an experiment and the federal officials know exactly what they are doing.